While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages ...

Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of ...

Novo Nordisk ( NVO) has said in a note published by the European Medicines Agency that the supply shortage of its diabetes ...

A woman who used the semaglutide drugs Wegovy and Ozempic to lose weight and treat diabetes says the drugmaker didn't ...

However, various potential headwinds have popped up that could disrupt Ozempic's progress. One of them is competition. Novo ...

The European market is facing shortages of Novo Nordisk's (NYSE: NVO) injectable glucagon-like peptide-1 receptor agonist ...

Novo Nordisk 's ( NVO 1.19%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is ...

Doctors had to remove parts of her intestines due to what she claims were side effects from taking weight-loss medication ...

Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. | The company and the European ...

Blockbuster weight loss drugs have been arguably the biggest health story of the last several years — and there are no signs ...